Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

KENILWORTH, N.J., May 18, 2007 /PRNewswire-FirstCall/ -- A total of 20 oral and poster presentations on clinical studies with Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C virus (HCV) infection, as well as boceprevir (SCH 503034), the company's investigational oral HCV protease inhibitor currently in Phase II clinical development, will be presented by leading researchers at the 38th annual Digestive Disease Week (DDW) meeting to be held at the Washington Convention Center in Washington, D.C., May 20-23.

Hepatitis C is the most common blood-borne infection in America and the most common form of liver disease, affecting nearly 5 million people in the United States and 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States.

PEGINTRON

Clinical investigators will present findings at DDW from numerous PEGINTRON studies evaluating patient response to therapy at certain treatment milestones, an approach that is aimed at individualizing treatment for patients. Schering-Plough also is exploring novel therapeutic approaches with PEGINTRON in combination with investigational antiviral agents to optimize treatment for patients with more difficult-to-treat forms of the disease, such as patients who were nonresponders to previous therapy.

Boceprevir (SCH 503034)

Schering-Plough is undertaking a large, fully integrated clinical development program for its oral HCV protease inhibitor boceprevir, with the goal of developing new strategies for improving treatment outcomes for patients with hepatitis C.

At DDW, Schering-Plough will present results of in vitro studies conducted in collaboration with Wyeth/ViroPharma of boceprevir in combination with their investigational non-nucl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
(Date:5/22/2015)... 2015 According to a new ... (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive ... by End Users - Global Forecast to 2020", published ... to reach $736.85 Million by 2020 from $452.36 Million ... Browse 71 market data Tables and 90 ...
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Biodel Inc. (Nasdaq: BIOD ) today announced ... will be presenting at the 6th Annual JMP Securities Healthcare ... presentation is scheduled for Tuesday, September 27, 2011 at 8:30 ... webcast or a replay of the presentation, please visit the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619265/Generic-Drugs-The-Global-Market--Focus-on-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment THIS ... examination of the strategies employed by companies ...
Cached Medicine Technology:Generic Drugs: The Global Market--Focus on Europe 2Generic Drugs: The Global Market--Focus on Europe 3Generic Drugs: The Global Market--Focus on Europe 4Generic Drugs: The Global Market--Focus on Europe 5Generic Drugs: The Global Market--Focus on Europe 6Generic Drugs: The Global Market--Focus on Europe 7Generic Drugs: The Global Market--Focus on Europe 8Generic Drugs: The Global Market--Focus on Europe 9Generic Drugs: The Global Market--Focus on Europe 10
(Date:5/23/2015)... Beach, CA (PRWEB) May 23, 2015 Dr. ... Beach, California, has just posted a new article ... gauge repair. As Dr Benvenuti explained in the ... wear enlarged plugs in their earlobes. , Known as “gauging,” ... the earlobe hole, which Dr. Benvenuti said will eventually stretch ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 On Wednesday, ... that, “the company has been the target of a ... part of the company’s ongoing Information Technology (IT) security ... insurers.” , The most notable attack on health ... Anthem Inc., the nation’s second largest health insurer, revealed ...
(Date:5/23/2015)... May 23, 2015 Manufacturers are now required ... Factor (HSPF) of 8.2. Experts in the field agree that ... consumers. , The HSPF score is what miles per gallon ... efficient the unit. Although the minimum HSPF score has been ... with an HSPF score north of 12. Indeed, the regulation ...
(Date:5/23/2015)... Janesville, WI (PRWEB) May 23, 2015 ... Mercy Acceleration at the Sports Medicine and Rehabilitation Center, ... running clinic program, Mondays, June 1-July 20, 5:30-6:30 pm. ... MS, USAT coach, and Laurie Finke, RN, BSN, who ... flexibility exercises, education on nutrition, running mechanics and show ...
(Date:5/23/2015)... MD (PRWEB) May 23, 2015 Injury lawyer ... that has been passed by the Maryland legislature but which ... “The Maryland General Assembly passed HB 449 with ... Governor has not signed it into law. This bill ensures ... Evidence is growing that demonstrates the danger of fracking to ...
Breaking Medicine News(10 mins):Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3
... organizations are joining forces to develop new drugs and ... of lives in the developing world each year. Those ... conditions. That,s the topic of the cover story scheduled ... ACS, weekly newsmagazine. C&EN Senior Editor Lisa Jarvis ...
... rich and poor could save 1.5 million lives a year, ... the income gap between the richest and poorest people in ... new study claims. , American and Japanese researchers analyzed data ... took part in previous studies and found that those living ...
... die from cardiovascular disease, study finds , WEDNESDAY, Nov. 11 ... old age, a French study has found that seniors who ... cardiovascular disease than are fast walkers. , The researchers measured ... women, ages 65 to 85 -- and collected medical and ...
... ... , ... 11, 2009 -- Potomac Conservancy today released its third annual State of the Nation’s ... that disrupt the endocrine system, which regulates the normal growth and sexual development of vertebrate ...
... , WHAT: The issue of uninsured Americans takes center ... Center, which served as a temporary medical clinic in the ... office for a day with free health care for uninsured ... treated by several hundred physicians and other volunteers at the ...
... time when Americans are spending $50 billion dollars annually on ... is on a mission to alleviate their anguish with plush ... bedding accessory, Pillo1. The first eco luxe neck pillow, Pillo1 ... soy-based foam and Talalay latex, a naturally-derived and renewable resource ...
Cached Medicine News:Health News:The New Pollutants Brewing in Our Water 2Health News:The New Pollutants Brewing in Our Water 3Health News:The New Pollutants Brewing in Our Water 4Health News:Surgeon-Approved, Pro-Athlete Chiropractor Breaks the $50 Billion Neck Pain Cycle With Launch of Pillo1, First Eco-Luxe Neck Pillow 2
... Suture™ VERSAPORT™ PLUS V2 RT single-use obturator has ... shield. , ,The Auto Suture™ VERSAPORT™ PLUS ... -11, 5-12, 11 mm and 12 mm diameters ... mm and 5 mm short single-use obturators are ...
... The Auto Suture™ VERSAPORT™ PLUS RPF trocar ... mm long, 5 mm-11 mm, 5 mm-12 mm, ... sleeve and shield. , ,The VERSAPORT™ PLUS ... a spring-loaded shield. Upon entry into a free ...
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Medicine Products: